Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Dr Reddys Laboratories, says Sukhani

      Sudarshan Sukhani of s2analytics.com is bullish on Dr Reddys Laboratories and recommends buying the stock. "It has been making new lifetime highs," he adds.

    • Super Six stocks you can bet on July 10

      Rajesh Jain of Religare Securities suggests buying Sesa Goa at its support of Rs 140-142 levels, keeping a closing stop loss below Rs 138 for higher target of more than Rs 150 in coming days.

    • Buy HCL Tech, Infosys, Wipro: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com says buy HCL Techologies, Infosys and Wipro.

    • Buy Dr Reddys Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddys Laboratories for short-term.

    • Sell Ranbaxy Laboratories on pullback: Hemant Thukral

      Hemant Thukral of Aditya Birla Money says one may short Ranbaxy Labs around Rs 325-330 levels.

    • Go long on Dr Reddys Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends to buy Dr Reddys Laboratories and go long as it has just emerged into life-time new highs.

    • Don't buy Sun Pharma, Dr Reddys, Cipla: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com said he would not be a buyer in Sun Pharmaceuticals, Dr Reddys Laboratories and Cipla.

    • Super Six stocks you can bet on June 17

      Manas Jaiswal of manasjaiswal.com recommends buying Future Retail and Gujarat State Petronet.

    • Buy Dr Reddys Lab, advises Sudarshan Sukhani

      Dr Reddys Laboratories is a buying opportunity and if it does not collapse then the chart is suggesting that it can touch new highs: Sudarshan Sukhani of s2analytics.com.

    • Citi view: How pharma sector is looking post Q4 debacle

      Prashant Nair of Citi India told CNBC-TV18 that the pharma sector's valuations in current market downturn situation has held up well. He presents his views on buzzing stocks from the sector.

    • Upbeat on Dr Reddys Labs, Sun Pharma, Cipla: Sukhani

      Sudarshan Sukhani of s2analytics.com says he is upbeat on Dr Reddys Labs, Sun Pharmaceutical and Cipla.

    • Check out Dipan Mehta's top bets in IT & pharma space

      Dipan Mehta is overweight on IT sector with rupee depreciating. Among the pharma stocks, he likes Sun Pharma, Dr Reddy's, Wockhardt and Cadila.

    • Check out Tulsian's bets in IT & pharma space

      SP Tulsian of sptulsian.com advised good ideas in the IT and pharma space. One can look for few IT stocks like Hexaware Technologies, Geometric at the current level.

    • Super Six stocks you can bet on June 10

      Vishal Malkan of malkansview.com advised buying Dr Reddys Labs and TCS. Meanwhile, Gaurav Ratnaparkhi of Sharekhan recommended selling Reliance Power and Future Retail.

    • Buy TCS, Dr Reddys Labs on decline, says Sukhani

      Sudarshan Sukhani of s2analytics.com advised buying TCS and Dr Reddys Labs on decline.

    • Check out: Top intraday picks for June 05

      Amit Gupta of icicidirect.com recommends going long in Dr Reddys Laboratories and suggest to take short call on Punjab National Bank.

    • Dr Reddys Labs, Cipla look attractive: Sukhani

      Dr Reddys Labs and Cipla are looking attractive at current levels. One can avoid Ranbaxy Labs, says Sudarshan Sukhani of s2analytics.com.

    • Buy Dr Reddys Laboratories, says Sukhani

      One can buy Dr Reddys Laboratories, says Sudarshan Sukhani of s2analytics.com. "When the Nifty corrected 250 points, DRL consolidated. This consolidation probably could easily breakout today," he adds.

    • 6 stocks likely to see lot of action today

      Vishal Kshatriya of Edelweiss is bullish on Zee Entertainment Enterprises and recommends going long in a range of Rs 234-235 with a target of Rs 255 and stop loss below Rs 228.

    • Go long in Dr Reddys Labs, Lupin: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Brokers advises to go long in Dr Reddys Laboratories and Lupin at current levels.

    • Dr Reddy‘s Labs should move up to Rs 2175-2180: Thukral

      Aditya Birla Money‘s Hemant Thukral feels Dr Reddy‘s Labs should move up to Rs 2,175-Rs 2,180 in immediate short-term.

    • Sun Pharma, Lupin, Dr Reddys top picks: Baliga

      Sun Pharmaceutical Industries, Lupin and Dr Reddys Laboratories are top three picks in the pharma sector, says Ambareesh Baliga of Edelweiss Financial Services.

    • Go long on Dr Reddys Labs, may hit Rs 2220: ICICI Direct

      Amit Gupta of ICICI Direct feels the stock may surpass Rs 2160 and meet Rs 2220 level. He advises to play long in the stock right now with stop loss around Rs 2030-2040.

    • Prefer Lupin, Dr Reddys in pharma space: Dhirendra Tiwari

      Dhirendra Tiwari of Antique Institutional Equities said Dr Reddys Labs and Lupin would remain his preferred pick within the pharmaceutical space.

    • Buy Dr Reddys Labs, says Sudarshan Sukhani

      Dr Reddys Laboratories had a small correction which may be over and one can think of buying it, says Sudarshan Sukhani of s2analytics.com.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347